Click on a filter below to refine your search. Remove a filter to broaden your search.
Two trials show a lower amyloid plaque burden with gantenerumab versus placebo at 116 weeks.
An increased risk for Alzheimer’s disease and related dementia was seen in association with higher and lower versus middle quintile of HDL-C.
Objectively assessed VMS (so-called hot flashes), including sleep VMS, are associated with significantly lower amyloid-β42/40.
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636